The Protocol and Data Management Office (PDMO) of the University of Chicago Cancer Research Center (UCCRC) is a shared resource that provides central management and oversight functions for coordinating, facilitating, and reporting on the cancer clinical trials of the University of Chicago. It interacts closely with the Biostatistics and Information Technology facility (BIT) and the Protocol Review and Monitoring System (PRMS) to maintain high quality data, regulatory compliance, and centralized lists of active protocols with accrual status for use by UCCRC investigators. Dr. Gini Fleming replaced Dr. Everett Vokes as Director of this facility during the past grant period.
The specific aims of the PDMO are; to facilitate and coordinate review and approval of protocols by both the UCCRC Clinical Trials Review Committee (CTRC) and the University of Chicago Institutional Review Board (IRB), and maintain records of correspondence with both committees; To monitor data quality and protocol compliance by periodic audits of all in-house protocols; To assure patient safety and regulatory compliance with Federal guidelines for investigational drug use and toxicity reporting through protocol audits and a centralized Adverse Event (AE) reporting system which confirms that all appropriate NCI and other agencies are notified of serious events; To facilitate Federal reporting requirements such as CDUS reports on phase II network trials and annual IND reports; To provide a centralized database of active studies and patients accrued to cancer clinical trials for use by investigators and the PRMS; To provide the centralized regulatory and data management coordination needed for the conduct of studies through a network of affiliated institutions; and To provide training and education to new investigators, nurses, and data management personnel in the technical aspects of clinical research and good clinical practice.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA014599-28S1
Application #
6664412
Study Section
Project Start
2002-05-15
Project End
2003-03-31
Budget Start
Budget End
Support Year
28
Fiscal Year
2002
Total Cost
Indirect Cost
Name
University of Chicago
Department
Type
DUNS #
225410919
City
Chicago
State
IL
Country
United States
Zip Code
60637
Trujillo, Jonathan A; Sweis, Randy F; Bao, Riyue et al. (2018) T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection. Cancer Immunol Res 6:990-1000
Zeng, Zongyue; Huang, Bo; Huang, Shifeng et al. (2018) The development of a sensitive fluorescent protein-based transcript reporter for high throughput screening of negative modulators of lncRNAs. Genes Dis 5:62-74
Lee, Ji-Hye; Park, Beom Seok; Han, Kang R et al. (2018) Insight Into the Interaction Between RNA Polymerase and VPg for Murine Norovirus Replication. Front Microbiol 9:1466
Cheng, Jason X; Chen, Li; Li, Yuan et al. (2018) RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia. Nat Commun 9:1163
Johnson, Marianna B; Hoffmann, Joscelyn N; You, Hannah M et al. (2018) Psychosocial Stress Exposure Disrupts Mammary Gland Development. J Mammary Gland Biol Neoplasia 23:59-73
Sweis, Randy F; Zha, Yuanyuan; Pass, Lomax et al. (2018) Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer. J Immunother Cancer 6:24
Kathayat, Rahul S; Cao, Yang; Elvira, Pablo D et al. (2018) Active and dynamic mitochondrial S-depalmitoylation revealed by targeted fluorescent probes. Nat Commun 9:334
Liu, Jun; Eckert, Mark A; Harada, Bryan T et al. (2018) m6A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. Nat Cell Biol 20:1074-1083
Bhanvadia, Raj R; VanOpstall, Calvin; Brechka, Hannah et al. (2018) MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease. Clin Cancer Res 24:3668-3680
Wood, Kevin; Byron, Elizabeth; Janisch, Linda et al. (2018) Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms. Am J Clin Oncol 41:963-966

Showing the most recent 10 out of 668 publications